Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.

Détails

ID Serval
serval:BIB_A58FC0B67AAE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.
Périodique
American Journal of Tropical Medicine and Hygiene
Auteur(s)
Senn N., D'Acremont V., Landry P., Genton B.
ISSN
0002-9637 (Print)
ISSN-L
0002-9637
Statut éditorial
Publié
Date de publication
2007
Volume
77
Numéro
6
Pages
1010-1014
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Three different drugs (mefloquine, atovaquone/proguanil, doxycycline) are recommended for malaria chemoprophylaxis, each with approximately the same efficacy but various adverse event profiles, regimens, and prices. We investigated which medication the travelers would have chosen on the basis of written evidence-based information and the impact that pretravel consultation had on their decision. A prospective study was performed in a travel clinic and private practice, and 1073 travelers were included; 45% chose mefloquine (Lariam or Mephaquine), 21% atovaquone/proguanil (Malarone), 18% doxycycline (Supracycline), 5% "no prophylaxis," and 11% "do not know." Lariam was principally chosen because of prior experience (38%), Mephaquine because of low price (34%), and doxycycline and Malarone because of the profile of adverse events (55% and 43%, respectively). Based on objective written information, travelers most frequently chose mefloquine for chemoprophylaxis. This suggests that evidence-based information weighs more heavily than negative publicity. Taking into account the perspective of the user should improve appropriateness of the pretravel advice.
Mots-clé
Adolescent, Adult, Antimalarials/adverse effects, Antimalarials/economics, Atovaquone/adverse effects, Atovaquone/economics, Consumer Health Information, Decision Making, Doxycycline/adverse effects, Doxycycline/economics, Drug Combinations, Female, Humans, Malaria/drug therapy, Malaria/prevention & control, Male, Mefloquine/adverse effects, Mefloquine/economics, Middle Aged, Proguanil/adverse effects, Proguanil/economics, Prospective Studies, Switzerland, Time Factors, Travel
Pubmed
Web of science
Création de la notice
03/07/2010 9:25
Dernière modification de la notice
20/08/2019 16:10
Données d'usage